logo
Share SHARE
FONT-SIZE Plus   Neg

Boston Scientific Begins Trial To Study Neurostimulation For Migraine Treatment

Boston Scientific Corporation(BSX), a maker of medical devices, Friday said it launched a clinical trial, OPTIMISE, to find out if occipital nerve stimulation or ONS using the Precision System can safely and effectively treat chronic migraine when used in conjunction with anti-migraine medications. The multi-center, randomized, placebo-controlled study is expected to be used to support various regulatory approvals of this novel therapy for chronic migraine.

With ONS, a small programmable implanted device sends electrical impulses to the greater occipital nerve, which runs from the top of the spinal cord to the base of the scalp. The Precision System for chronic migraine is investigational and is currently available as an approved treatment in the U.S., Canada, Europe and Australia as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome and intractable low back pain and leg pain.

"We believe that the Boston Scientific neurostimulation therapy for migraine has enormous potential to help migraine sufferers worldwide..." said Maulik Nanavaty, president, Neuromodulation, Boston Scientific.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Etihad Airway's Chief Executive Officer James Hogan will leave in the second half this year. Hogan has been with the Abu Dhabi based aviation group since 2006. Chief Financial Officer James Rigney also will depart from service. Seafood lovers must now be prepared to dole out more cash than before for salmon. The price of salmon has surged globally and is now at historic highs amid acute outbreaks of sea lice. According to data from the Nasdaq Salmon Index, the price of salmon has risen by more than 15 percent in the last three months. Health-food restaurant chain Freshii Inc. has increased the price range for its initial public offering in Canada. Freshii has raised the price range for its IPO to C$10 to C$11.50 per share from the prior range of C$8.50 to C$10.0 per share, BNN reported.
comments powered by Disqus
Follow RTT